The proposed strategy with additional INF-beta-IL-2 sequence in endocrine-dependent metastatic ER+ breast cancer patients seem to be effective, at least as effective as CDK 4/6 inhibitors but with a less harmful treatment profile. This evidence concerns the gene IL2 and breast carcinoma.